The ten-year collaboration, announced Dec. 21, gives Tempus and PH.AI access to de-identified data from over a growing database of more than a million records contained in CancerLinQ.
ASCO and its new commercial partners will continue to expand CancerLinQ and, at the same time, look for better ways to aggregate and mine the data. The data could be used in drug development as well as scientific projects and quality initiatives.